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Summary Diabetes is associated with a marked increased risk of atherosclerotic vascular
disorders, including coronary, cerebrovascular, and peripheral artery disease. Cardiovascular
disease (CVD) could account for disabilities and high mortality rates in patients with dia-
betes. Conventional risk factors, including hyperlipidemia, hypertension, smoking, obesity,
lack of exercise, and a positive family history, contribute similarly to macrovascular compli-
cations in type 2 diabetic patients and non-diabetic subjects. The levels of these factors in
diabetic patients are certainly increased, but not enough to explain the exaggerated risk for
macrovascular complications in the diabetic population. Furthermore, recently, macrovascu-
lar complications of diabetes have been shown to start before the onset of diabetes. Indeed,
several clinical studies have conﬁrmed the increased risk of CVD in patients with impaired glu-
cose tolerance (IGT). Since insulin resistance-related postprandial metabolic derangements are
thought to play a central role in the development and progression of CVD in patients with IGT,
amelioration of postprandial metabolic disturbance is a therapeutic target for the prevention of
CVD in these high-risk patients. Therefore, in this paper, we review the molecular mechanisms
for the increased risk of CVD in recent onset diabetes mellitus, especially focusing on postpran-
dial dysmetabolism. We also discuss here the potential therapeutic strategies that specially
target the mechanisms responsible for vascular alterations in diabetes.
© 2011 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
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ntroduction
therosclerotic arterial disease may be manifested clinically
s cardiovascular disease (CVD). Diabetes is a major risk fac-
or for cardiovascular morbidity and mortality. Indeed, the
ncidence of CVD is 2—4 times greater in diabetic patients
han in the general population [1]. CVD is responsible for
bout 70% of all causes of death in patients with type 2
iabetes [2]. Conventional risk factors, including hyperlipi-
emia, hypertension, smoking, obesity, lack of exercise, and
positive family history, contribute similarly to CVD in type 2
iabetic patients and non-diabetic subjects [2]. The associa-
ion rates of these factors in diabetic patients are certainly
igh, but not enough to explain the exaggerated risk for
VD in the diabetic population. Therefore, diabetes-related
peciﬁc risk factors should be involved in the excess risk in
iabetic patients.
Macrovascular complications of diabetes have been
hown to start before the onset of diabetes [3].
everal clinical studies have conﬁrmed the increased
isk of CVD in patients with impaired glucose toler-
nce (IGT) [4,5]. Insulin resistance could explain the
ncreased risk for CVD in patients with IGT because
nsulin resistance is associated with IGT and postprandial
yperglycemia/hyperlipidemia [5]. Further, recently, insulin
esistance-related postprandial dysmetabolism, including
ostprandial hyperglycemia/hyperlipidemia, was shown to
e of greater importance in CVD in patients with type 2 dia-
etes [5]. These observations suggest that amelioration of
ostprandial metabolic derangements is a therapeutic tar-
et for preventing CVD in these patients. Therefore, in this
eview, we discuss the molecular mechanisms for acceler-
ted atherosclerosis and increased risk for CVD in patients
ith recent onset diabetes mellitus, especially focusing
n postprandial dysmetabolism. We also discuss here the
otential therapeutic strategies that specially target the
echanisms responsible for vascular alterations in diabetes.
ostprandial dysmetabolism and CVD in
iabetes
pidemiological link
everal prospective studies have shown that hyperglycemia
tself is clearly involved in predicting CVD [6]. In newly
iagnosed type 2 diabetes, 10-year cardiovascular mortal-
ty increases three-fold by tertiles of blood glucose and
lycated hemoglobin (Hb) A1c [7]. There is a signiﬁcant
ncrease in the risk of CVD death and all CVD events in
ype 2 diabetic subjects with HbA1c levels higher than 7.0%
glucose control effectively reduced microvascular compli-
cations in type 2 diabetic patients [9]. However, the risk of
myocardial infarction was reduced slightly but not signif-
icantly by about 15%, and the risk reduction of myocardial
infarction by control of blood glucose is less than that by the
treatment of hypertension (21%) or hypercholesterolemia
(31%). Since the reduction of hyperglycemia was small and
the intervention period was relatively short, the beneﬁcial
effects of blood glucose control on CVD may be underesti-
mated in this trial. Indeed, in the 10-year follow-up study
of UKPDS, UKPDS80, despite an early loss of glycemic differ-
ences between the original intensive therapy group and the
conventional one, a continued reduction in microvascular
risk and emergent risk reductions for myocardial infarction
and death from any cause were observed [10]. These ﬁnd-
ings demonstrate that so-called ‘metabolic memory’ could
cause chronic abnormalities and exert carry-over effects in
diabetic vessels that are not easily reversed, even by sub-
sequent, relatively good control of blood glucose. These
observations suggest a long-term beneﬁcial inﬂuence of
early metabolic control, that is, legacy effects, on the risk of
vascular complications and death in patients with diabetes
[11].
Risk of CVD begins to increase before the onset of dia-
betes. Several studies have conﬁrmed the increased risk
of CVD in patients with IGT [3,4]. Furthermore, insulin
resistance in the absence of overt diabetes has been asso-
ciated with endothelial dysfunction, a surrogate marker
of atherosclerosis [12,13]. Therefore, atherosclerotic pro-
cess may actually begin earlier in the spectrum of insulin
resistance. Insulin resistance-associated postprandial hyper-
glycemia may play a role in the development and progression
of CVD in patients with recently diagnosed diabetes [5].
Indeed, in the Funagata diabetes study, analysis of sur-
vival rates concluded that IGT, but not impaired fasting
glucose, was a risk factor for CVD [14]. The DECODE study
revealed that 2-h post-load hyperglycemia was associated
with an increased risk of mortality from CVD, indepen-
dent of fasting plasma glucose [15]. This study also showed
that abnormalities in 2-h plasma glucose were better pre-
dictors of mortality from CVD and non-CVD than fasting
glucose alone. Furthermore, the Diabetes Intervention Study
(DIS) identiﬁed postprandial hyperglycemia to be an inde-
pendent risk factor for myocardial infarction and all-cause
mortality [16]. Moreover, postprandial hyperglycemia has
been shown to be associated with endothelial dysfunction
and increased intima-media thickness (IMT) as well as a
higher prevalence of atherosclerotic plaques of the com-
mon carotid arteries, thus suggesting that mild-to-moderate
postprandial hyperglycemia is involved in early atheroscle-
rosis [17—19]. The relative contribution of postprandialompared with diabetic subjects with lower HbA1c [8].
he conclusive answer to the question on the existence of
ause—effect relationship between hyperglycemia and CVD
ay derive from intervention studies. In the United Kingdom
rospective Diabetes Study (UKPDS) study, intensive blood
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Hlucose decreased progressively from the lowest to the high-
st quintile of HbA1c, whereas the relative contribution of
asting glucose increased gradually with increasing levels of
bA1c [20]. These observations suggest that the decrease of
bA1c levels could not necessarily reﬂect the reduction of
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postprandial hyperglycemia, especially in poorly controlled
diabetic patients. This could partly explain why decreased
HbA1c levels did not signiﬁcantly lead to the reduction of
the risk for CVD in the UKPDS trial.
There are several papers to suggest the link between
postprandial hyperlipidemia and CVD in diabetic and non-
diabetic subjects [21—23]. In a prospective cohort study
of 7587 women and 6394 men from the general popula-
tion of Copenhagen, elevated non-fasting triglyceride levels
were associated with increased risk of myocardial infarc-
tion, ischemic heart disease, and death in both men and
women [21]. Further, non-fasting serum triglycerides were
reported to independently predict the incidence of coro-
nary heart disease among Japanese men and women who
possess low mean values of total cholesterol as well [22].
A recent meta-analysis of 27 prospective studies of west-
ern populations reported that non-fasting triglycerides were
independently associated with CVD [23].
Possible molecular mechanisms underlying the link
In vitro, intermittent and constant high glucose have been
shown to not only enhance apoptotic cell death, but also
stimulate expression of adhesion molecules (intercellu-
lar adhesion molecule-1 (ICAM-1), vascular cell adhesion
molecule-1 (VCAM-1), E-selectin) as well as interleukin-6
(IL-6) in cultured endothelial cells through oxidative stress
generation via both protein kinase C-dependent activa-
tion of NADPH oxidase and mitochondrial electron transport
chain [24,25]. The deleterious effects are evenmore evident
in intermittent high glucose. These observations suggest
that postprandial hyperglycemic spike-evoked oxidative
stress generation may be involved in the development of
vascular injury in diabetes.
Postprandial hyperglycemia induces oxidative stress gen-
eration in diabetic patients as well [26,27]. Monnier et al.
reported that urinary excretion of an oxidative stress
marker, 8-iso prostaglandin F2, was independently associ-
ated with mean amplitude of glycemic excursions in type 2
diabetes, thus suggesting that glucose ﬂuctuations during
postprandial periods could exhibit a more speciﬁc trig-
gering effect on oxidative stress generation than chronic
sustained hyperglycemia [26]. Under oxidative stress con-
ditions, nitric oxide (NO) undergoes a rapid reaction with
superoxide anions to form peroxynitrite, a toxic metabo-
lite of NO, which could cause endothelial dysfunction, an
initial step of atherosclerosis [11,12]. Furthermore, the
loss of NO permits increased activity of the redox-sensitive
transcription factor nuclear factor-B (NF-B), which could
lead to vascular inﬂammation and altered gene expression
of cytokines and growth factors [11,12]. Moreover, post-
prandial hyperglycemia-elicited oxidative stress generation
induces platelet activation and thrombin generation and
inactivates ﬁbrinolytic systems, thereby participating in the
progression of atherosclerosis in diabetes [27,28].
Postprandial triglyceride-rich lipoproteins induce NF-B
activation in endothelial cells and subsequently up-regulate
expression of several pro-inﬂammatory genes including
ICAM-1, VCAM-1, monocyte chemoattractant protein-1
(MCP-1), and IL-6 [29]. In addition, postprandial hyper-
triglyceridemia has been shown to be independently
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ssociated with carotid IMT in patients with type 2 diabetes
30]. The positive relationships among postprandial lipi-
emia, endothelial dysfunction, and oxidative stress were
lso reported in type 2 diabetic patients [31]. Further,
ostprandial hypertriglyceridemia was more prominent in
ype 2 diabetic patients with microalbuminuria, thus partly
xplaining the excess risk of CVD in these subjects [32].
eriello and colleagues have shown that postprandial hyper-
lycemia and/or hypertriglyceridemia are associated with
n increase of plasma levels of nitrotyrosine and inﬂam-
atory and thrombogenic biomarkers such as IL-6, soluble
CAM-1, soluble VCAM-1 and prothrombin fragment 1 + 2
27,28,33]. They showed that postprandial dysmetabolism
as accompanied with oxidative stress and endothelial dys-
unction in diabetic patients as well.
We have previously shown that glyceraldehyde can
apidly react with amino groups of proteins to form
lyceraldehyde-derived advanced glycation end products
AGEs) in vivo, which elicit oxidative stress generation
nd evoke vascular inﬂammation and insulin resistance in
atients with diabetes [34,35]. Further, we have recently
ound that serum levels of glyceraldehyde-derived AGEs
ather than HbA1c could reﬂect cumulative postprandial
yperglycemia in oral hypoglycemic agent-naive type 2
iabetic patients [36]. In addition, increased production
f methylglyoxal and 3-deoxyglucosone, two highly reac-
ive precursors of AGEs has been reported to occur with
reater postprandial glycemic excursions in type 1 diabetic
atients, whereas HbA1c does not reﬂect these differ-
nces [37]. Given the deleterious effects of glyceraldehyde-,
ethylglyoxal-, and 3-deoxyglucosone-derived AGEs on CVD
n diabetes [34,35], postprandial hyperglycemia may pro-
ote atherosclerosis partly via activation of AGEs-oxidative
tress system.
otential therapeutic strategies for postprandial
ysmetabolism
dministration of acarbose, an -glucosidase inhibitor, for
2weeks in non-obese type 2 diabetic rats improved post-
randial hyperglycemia, postprandial insulin level, triglyc-
ride, and fatty acid levels [38]. Furthermore, acarbose
fﬁciently reduced the number of monocytes adherent to
ortic endothelial layer, improved acethycholine-dependent
asodilation, and reduced intimal thickening of the aorta.
hese ﬁndings may suggest that acarbose could exert
theroprotective properties, at least in part, by suppressing
onocyte adhesion to endothelial cells via the inhibition of
epetitive postprandial hyperglycemia in diabetes.
It is well known that postprandial metabolic abnormal-
ties can be induced in rats by fructose-rich diets [5].
ndeed, we have previously shown that hyperinsulinemia and
ypertriglyceridemia with lowered high-density lipoprotein
HDL)-cholesterol levels developed in rats that were fed
high fructose diet for 4weeks [5]. Acarbose treatment
mproved insulin resistance in fructose-fed rats [5]. The
reatment also increased HDL-cholesterol levels and inhib-
ted the elevation of systolic blood pressure. Furthermore,
ral administration of acarbose decreased serum levels of
CP-1 and its expression in aorta in fructose-fed rats. MCP-
has been postulated to play an important role in the early
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hase of atherosclerosis by initiating monocyte recruitment
o the vessel wall, and its expression is found to be ele-
ated in human atherosclerotic plaques [39]. Moreover, the
elective targeting of CCR2, the receptor for MCP-1, was
hown to markedly decrease atheromatous lesion forma-
ion in apoE knockout mice [39]. In addition, MCP-1 has
ontributed to insulin resistance by evoking inﬂammatory
eactions in adipose tissues as well [40]. Taken together,
hese observations suggest that acarbose may play a pro-
ective role against atherosclerosis and insulin resistance in
iabetes by suppressing MCP-1-induced inﬂammatory reac-
ions via amelioration of postprandial dysmetabolism.
In patients with type 2 diabetes, acarbose treatment was
hown to not only increase serum lipoprotein lipase mass
evels [41], but also decrease circulating levels of oxidized
ow-density lipoprotein (LDL)-cholesterol, plasminogen acti-
ator inhibitor-1 and ﬁbrinogen [42]. Further, a single
dministration of acarbose has been reported to improve
ostprandial glucose excursion and endothelial dysfunction
n type 2 diabetic patients as well [43]. Acarbose also atten-
ated several of the characteristic hepatic alterations of
on-alcoholic steatohepatitis, a hepatic manifestation of
nsulin resistance: there was less steatosis and inﬂamma-
ion with a signiﬁcant reduction in tumor necrosis factor-
xpression [5].
The STOP-NIDDM trial revealed that acarbose improved
ostprandial hyperglycemia and subsequently reduced the
isk of diabetes in patients with IGT [44]. Acarbose treat-
ent was also found to slow the progression of IMT
f the carotid arteries and to reduce the incidence of
VD and newly diagnosed hypertension in IGT patients
45]. Acarbose signiﬁcantly reduced body weight and
ncreased HDL-cholesterol levels in these patients over
years. Furthermore, a meta-analysis of seven double-blind
lacebo-controlled, randomized trials has shown that inter-
ention with acarbose prevents myocardial infarction and
VD in type 2 diabetic patients [5]. In this analysis, glycemic
ontrol, triglyceride levels, body weight, and systolic blood
ressure was also signiﬁcantly improved during acarbose
reatment. These observations suggest that prevention of
ostprandial hyperglycemia by acarbose may be a promis-
ng therapeutic strategy for reducing the increased risk for
iabetes, hypertension, dyslipidemia, obesity, and CVD in
atients with diabetes or the metabolic syndrome. Acarbose
s known to improve postprandial hyperglycemia by delay-
ng the release of glucose from complex carbohydrates in the
bsence of an increase in insulin secretion. Improvement of
ostprandial hyperglycemia itself could be associated with
melioration in insulin sensitivity.
Repaglinide, a rapid-onset/short-duration insulinotropic
gent, has been shown to decrease circulating inﬂam-
atory markers such as IL-6 and C-reactive protein and
egress carotid atherosclerosis by the control of postprandial
yperglycemia in patients with type 2 diabetes [46]. Admin-
stration of another rapid insulinotropic agent, mitiglinide,
igniﬁcantly decreased oxidative stress markers including
itrotyrosine and oxidized LDL levels and preserved total
adical-trapping anti-oxidant capacity in diabetic patients
s well [47]. In addition, as compared with regular insulin,
hort-acting insulin such as insulin aspart reduced the area
nder the curve for postprandial hyperglycemia and nitroty-
osine and preserved ﬂow-mediated vasodilation [17]. We
[S. Yamagishi
ave recently found that combination therapy with nateglin-
de and telmisartan could ameliorate insulin resistance in
ucker fatty rats by suppressing the AGEs-oxidative stress
xis in the liver [48]. These ﬁndings suggest that control of
xcessive glucose excursions by glinides or aspart, especially
n the postprandial state, may also become a novel thera-
eutic strategy for the prevention of insulin resistance and
VD in diabetes.
onclusions
s mentioned above, recent clinical studies have substanti-
ted the concept of ‘metabolic memory’ in the pathogenesis
f CVD in diabetes [34,35]. The biochemical nature of AGEs
nd their mode of actions are most compatible with the the-
ry ‘metabolic memory’ [34,35,49]. Further large clinical
tudies are needed to clarify whether aggressive treatment
or postprandial dysmetabolism could reduce the risk of CVD
n patients with recent onset diabetes by blocking the AGEs-
xidative tress axis.
cknowledgments
his work was supported in part by Grants of Collabora-
ion with Venture Companies Project from the Ministry of
ducation, Culture, Sports, Science and Technology, Japan
S.Y.).
eferences
[1] Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortal-
ity from coronary heart disease in subjects with type 2 diabetes
and in nondiabetic subjects with and without prior myocardial
infarction. N Engl J Med 1998;339:229—34.
[2] Laakso M. Hyperglycemia and cardiovascular disease in type 2
diabetes. Diabetes 1999;48:937—42.
[3] Pyorala K. Relationship of glucose tolerance and plasma insulin
to the incidence of coronary heart disease: results from two
population studies in Finland. Diabetes Care 1979;2:131—41.
[4] Fuller JH, Shipley MJ, Ros G, Jarrett RJ, Keen H. Coronary-
heart-disease risk and impaired glucose tolerance. The
Whitehall study. Lancet 1980;1:1373—6.
[5] Yamagishi S, Matsui T, Ueda S, Fukami K, Okuda S. Clinical
utility of acarbose, an alpha-glucosidase inhibitor in car-
diometabolic disorders. Curr Drug Metab 2009;10:159—63.
[6] Uusitupa MI, Niskanen LK, Siitonen O, Voutilainen E, Pyorala K.
Ten-year cardiovascular mortality in relation to risk factors and
abnormalities in lipoprotein composition in type 2 (non-insulin-
dependent) diabetic and non-diabetic subjects. Diabetologia
1993;36:1175—84.
[7] Kuusisto J, Mykkanen L, Pyorala K, Laakso M. NIDDM and its
metabolic control predict coronary heart disease in elderly
subjects. Diabetes 1994;43:960—7.
[8] Kuusisto J, Mykkanen L, Pyorala K, Laakso M. Non-
insulin-dependent diabetes and its metabolic control are
important predictors of stroke in elderly subjects. Stroke
1994;25:1157—64.
[9] UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-
glucose control with sulphonylureas or insulin compared with
conventional treatment and risk complications in patients with
type 2 diabetes (UKPDS 33). Lancet 1998;352:837—53.
10] Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year
follow-up of intensive glucose control in type 2 diabetes. N Engl
J Med 2008;359:1577—89.
[[
[
[
[
[
[
[
[
[
[
[
[
[Cardiovascular disease in recent onset diabetes mellitus
[11] Yamagishi S, Imaizumi T. Diabetic vascular complications:
pathophysiology, biochemical basis and potential therapeutic
strategy. Curr Pharm Des 2005;11:2279—99.
[12] Yamagishi S, Nakamura K, Matsui T. Potential utility of telmis-
artan, an angiotensin II type 1 receptor blocker with perox-
isome proliferator-activated receptor-gamma (PPAR-gamma)-
modulating activity for the treatment of cardiometabolic
disorders. Curr Mol Med 2007;7:463—9.
[13] Hsueh WA, Quinones MJ. Role of endothelial dysfunction in
insulin resistance. Am J Cardiol 2003;92:10J—7J.
[14] Tominaga M, Eguchi H, Manaka H, Igarashi K, Kato T, Sekikawa
A. Impaired glucose tolerance is a risk factor for cardiovas-
cular disease, but not impaired fasting glucose. The Funagata
Diabetes Study. Diabetes Care 1999;22:920—4.
[15] Glucose tolerance and mortality: comparison of WHO and
American Diabetes Association diagnostic criteria. The DECODE
study group. European Diabetes Epidemiology Group. Lancet
1999;354:617—21.
[16] Hanefeld M, Fischer S, Julius U, Schulze J, Schwanebeck
U, Schmechel H, Ziegelasch HJ, Lindner J. Risk factors for
myocardial infarction and death in newly detected NIDDM: the
Diabetes Intervention Study, 11-year follow-up. Diabetologia
1996;39:1577—83.
[17] Ceriello A, Cavarape A, Martinelli L, Da Ros R, Marra G,
Quagliaro L, Piconi L, Assaloni R, Motz E. The post-prandial
state in Type 2 diabetes and endothelial dysfunction: effects
of insulin aspart. Diabet Med 2004;21:171—5.
[18] Hanefeld M, Koehler C, Schaper F, Fuecker K, Henkel
E, Temelkova-Kurktschiev T. Postprandial plasma glucose is
an independent risk factor for increased carotid intima-
media thickness in non-diabetic individuals. Atherosclerosis
1999;144:229—35.
[19] Bonora E, Kiechl S, Oberhollenzer F, Egger G, Bonadonna RC,
Muggeo M, Willeit J. Impaired glucose tolerance, Type II dia-
betes mellitus and carotid atherosclerosis: prospective results
from the Bruneck Study. Diabetologia 2000;43:156—64.
[20] Monnier L, Lapinski H, Colette C. Contributions of fasting and
postprandial glucose increments to the overall diurnal hyper-
glycemia of type 2 diabetic patients: variations with increasing
levels of HbA(1c). Diabetes Care 2003;26:881—5.
[21] Nordestgaard BG, Benn M, Schnohr P, Tybjaerg-Hansen A.
Nonfasting triglycerides and risk of myocardial infarction,
ischemic heart disease, and death in men and women. JAMA
2007;298:299—308.
[22] Iso H, Naito Y, Sato S, Kitamura A, Okamura T, Sankai T, Shi-
mamoto T, Iida M, Komachi Y. Serum triglycerides and risk of
coronary heart disease among Japanese men and women. Am
J Epidemiol 2001;153:490—9.
[23] Kannel WB, Vasan RS. Triglycerides as vascular risk fac-
tors: new epidemiologic insights. Curr Opin Cardiol 2009;24:
345—50.
[24] Quagliaro L, Piconi L, Assaloni R, Da Ros R, Maier A, Zuo-
dar G, Ceriello A. Intermittent high glucose enhances ICAM-1
VCAM-1 and E-selectin expression in human umbilical vein
endothelial cells in culture: the distinct role of protein kinase
C and mitochondrial superoxide production. Atherosclerosis
2005;183:259—67.
[25] Ouagliaro L, Piconi L, Assaloni R, Martinelli L, Motz E, Ceriello
A. Intermittent high glucose enhances apoptosis related to
oxidative stress in human umbilical vein endothelial cells: the
role of protein kinase C and NAD(P)H-oxidase activation. Dia-
betes 2003;52:2795—804.
[26] Monnier L, Mas E, Ginet C, Michel F, Villon L, Cristol JP. Colette
C. Activation of oxidative stress by acute glucose ﬂuctuations
compared with sustained chronic hyperglycemia in patients
with type 2 diabetes. JAMA 2006;295:1681—7.
[27] Yu PC, Bosnyak Z, Ceriello A. The importance of glycated
haemoglobin (HbA(1c)) and postprandial glucose (PPG) control
[261
on cardiovascular outcomes in patients with type 2 diabetes.
Diabetes Res Clin Pract 2010;89:1—9.
28] Ceriello A, Giacomello R, Stel G, Motz E, Taboga C, Tonutti L,
Pirisi M, Falleti E, Bartoli E. Hyperglycemia-induced thrombin
formation in diabetes. The possible role of oxidative stress.
Diabetes 1995;44:924—8.
29] Norata GD, Grigore L, Raselli S, Redaelli L, Hamsten A, Maggi F,
Eriksson P, Catapano AL. Post-prandial endothelial dysfunction
in hypertriglyceridemic subjects: molecular mechanisms and
gene expression studies. Atherosclerosis 2007;193:321—7.
30] Teno S, Uto Y, Nagashima H, Endoh Y, Iwamoto Y, Omori Y,
Takizawa T. Association of postprandial hypertriglyceridemia
and carotid intima-media thickness in patients with type 2
diabetes. Diabetes Care 2000;23:1401—6.
31] Anderson RA, Evans ML, Ellis GR, Graham J, Morris K, Jackson
SK, Lewis MJ, Rees A, Frenneaux MP. The relationships between
post-prandial lipaemia, endothelial function and oxidative
stress in healthy individuals and patients with type 2 diabetes.
Atherosclerosis 2001;154:475—83.
32] Tentolouris N, Stylianou A, Lourida E, Perrea D, Kyriaki D,
Papavasiliou EC, Tselepis AD, Katsilambros N. High postprandial
triglyceridemia in patients with type 2 diabetes and microal-
buminuria. J Lipid Res 2007;48:218—25.
33] Ceriello A, Taboga C, Tonutti L, Quagliaro L, Piconi L, Bais B,
Da Ros R, Motz E. Evidence for an independent and cumulative
effect of postprandial hypertriglyceridemia and hyperglycemia
on endothelial dysfunction and oxidative stress generation:
effects of short- and long-term simvastatin treatment. Circu-
lation 2002;106:1211—8.
34] Yamagishi S. Advanced glycation end products and receptor-
oxidative stress system in diabetic vascular complications. Ther
Apher Dial 2009;13:534—9.
35] Yamagishi S, Nakamura K, Matsui T, Ueda S, Fukami K, Okuda S.
Agents that block advanced glycation end product (AGE)-RAGE
(receptor for AGEs)-oxidative stress system: a novel therapeu-
tic strategy for diabetic vascular complications. Expert Opin
Investig Drugs 2008;17:983—96.
36] Tsunosue M, Mashiko N, Ohta Y, Matsuo Y, Ueda K, Ninomiya M,
Tanaka S, Hoshiko M, Yoshiyama Y, Takeuchi M, Ueda S, Yam-
agishi S. An alpha-glucosidase inhibitor, acarbose treatment
decreases serum levels of glyceraldehyde-derived advanced
glycation end products (AGEs) in patients with type 2 diabetes.
Clin Exp Med 2010;10:139—41.
37] Beisswenger PJ, Howell SK, O’Dell RM, Wood ME, Touchette AD,
Szwergold BS. alpha-Dicarbonyls increase in the postprandial
period and reﬂect the degree of hyperglycemia. Diabetes Care
2001;24:726—32.
38] Azuma K, Toyofuku Y, Iesaki T, Otsuka A, Tanaka A, Mita T,
Hirose T, Tanaka Y, Daida H, Kawamori R, Watada H. Acarbose,
an alpha-glucosidase inhibitor, improves endothelial dysfunc-
tion in Goto-Kakizaki rats exhibiting repetitive blood glucose
ﬂuctuation. Biochem Biophys Res Commun 2006;345:688—93.
39] Yamagishi S, Nakamura K, Matsui T. Role of oxidative stress in
the development of vascular injury and its therapeutic inter-
vention by nifedipine. Curr Med Chem 2008;15:172—7.
40] Gustafson B, Hammarstedt A, Andersson CX, Smith U. Inﬂamed
adipose tissue: a culprit underlying the metabolic syn-
drome and atherosclerosis. Arterioscler Thromb Vasc Biol
2007;27:2276—83.
41] Oyama T, Saiki A, Endoh K, Ban N, Nagayama D, Ohhira M,
Koide N, Miyashita Y, Shirai K. Effect of acarbose, an alpha-
glucosidase inhibitor, on serum lipoprotein lipase mass levels
and common carotid artery intima-media thickness in type
2 diabetes mellitus treated by sulfonylurea. J Atheroscler
Thromb 2008;15:154—9.
42] Hasegawa G, Kajiyama S, Tanaka T, Imai S, Kozai H, Fujinami
A, Ohta M, Obayashi H, Park H, Nakano K, Tanaka M, Shiraishi
E, Fukui M, Yoshikawa T, Nakamura N. The alpha-glucosidase
2[
[
[
[
[
[62
inhibitor acarbose reduces the net electronegative charge of
low-density lipoprotein in patients with newly diagnosed type
2 diabetes. Clin Chim Acta 2008;390:110—4.
43] Shimabukuro M, Higa N, Chinen I, Yamakawa K, Takasu N.
Effects of a single administration of acarbose on postprandial
glucose excursion and endothelial dysfunction in type 2 dia-
betic patients: a randomized crossover study. J Clin Endocrinol
Metab 2006;91:837—42.
44] Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso
M, STOP-NIDDM Trail Research Group. Acarbose for prevention
of type 2 diabetes mellitus: the STOP-NIDDM randomised trial.
Lancet 2002;359:2072—7.45] Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso
M, STOP-NIDDM Trail Research Group. Acarbose treatment and
the risk of cardiovascular disease and hypertension in patients
with impaired glucose tolerance: the STOP-NIDDM trial. JAMA
2003;290:486—94.
[S. Yamagishi
46] Esposito K, Giugiano D, Nappo F, Marfella R, Campa-
nian Postprandial Hyperglycemia Study Group. Regression
of carotid atherosclerosis by control of postprandial hyper-
glycemia in type 2 diabetes mellitus. Circulation 2004;110:
214—9.
47] Ceriello A, Ouagliaro L, Catone B, Pascon R, Piazzola M, Bais
B, Marra G, Tonutti L, Taboga C, Motz E. Role of hyper-
glycemia in nitrotyrosine postprandial generation. Diabetes
Care 2002;25:1439—43.
48] Miura K, Kitahara Y, Kajioka T, Takeuchi M, Yamagishi S.
Combination therapy with nateglinide and telmisartan ame-
liorates insulin resistance in Zucker fatty rats by suppressing
advanced glycation end product receptor axis. Horm Metab Res
2010;(November) [Epub ahead of print].
49] Ceriello A. Hypothesis: ‘‘the metabolic memory’’, the new
challenge of diabetes. Diabetes Res Clin Pract 2009;86(Suppl.
1). S2—6.
